Add like
Add dislike
Add to saved papers

New insights into the Cyp51 contribution to azole resistance in Aspergillus section Nigri .

Invasive aspergillosis (IA) is a severe condition mainly caused by Aspergillus fumigatus , although other species of the genus, such as section Nigri members, can also be involved. Voriconazole (VRC) is the recommended treatment for IA; however, the prevalence of azole resistant Aspergillus isolates has alarmingly increased in recent years and the underlying resistance mechanisms in non- fumigatus species remain unclear. We have determined the in vitro susceptibility of 36 strains from section Nigri to VRC, posaconazole (POS) and itraconazole (ITC), and we have explored the role of Cyp51A and Cyp51B, both targets of azoles, in azole resistance. The three drugs were highly active; POS displayed the best in vitro activity while ITC and VRC showed Minimal Inhibitory Concentrations (MICs) above the stablished Epidemiological Cutoff Values (ECVs) in 9 % and 16 % of the strains, respectively. Furthermore, expression studies of cyp51A and cyp51B in control condition and after VRC exposure were performed in 14 strains with different VRC susceptibility. We found higher transcription of cyp51A, which was up-regulated upon VRC exposure, but no correlation between MICs and cyp51 transcription levels was observed. Additionally, cyp51A sequence analyses revealed non-synonymous mutations present in both, wild-type (wt) and non-wild type (non-wt) strains of A. niger and A. tubingensis. Nevertheless, a few mutations were exclusively present in non-wt A. tubingensis strains. Altogether, our results suggest that azole resistance in section Nigri is not clearly explained by Cyp51A protein alteration or by cyp51 gene up-regulation, which indicates that other mechanisms might be involved.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app